Pharmaceuticals

Samsung Biologics launches high-concentration formulation platform to accelerate high-dose drug development

* S-HiConTM is designed to maximize drug delivery and stability through high-concentration formulation * The platform can address challenges associated with viscosity and achieve stable liquid formulation for over 200 mg/mL subcutaneous administration INCHEON, South Korea, Oct. 14, 2024 /PRNe...

2024-10-14 19:00 1553

BioCity will present the late-breaking clinical trial data of its ETA selective antagonist SC0062 at the American Society of Nephrology (ASN) 2024 with simultaneous publication of the trial data in the Journal of the American Society of Nephrology (JASN)

SHANGHAI, Oct. 14, 2024 /PRNewswire/ -- BioCity Biopharma announced that a late-breaking clinical trial abstract of its endothelin receptor type A (ETA) selective antagonist SC0062 has been selected for oral presentation at ASN Kidney Week 2024 which will take place fromOctober 23 to 27 in San Di...

2024-10-14 15:38 1487

Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline

Expediting International Clinical Trials for Pivotal Products Key Participants Include International Long-Term and Healthcare Funds HONG KONG, Oct. 13, 2024 /PRNewswire/ -- Akeso Biopharma (9926. HK) ("Akeso", the "Company" ) announced that it has successfully raised approximately$250 million US...

2024-10-13 20:27 3357

Delegation of International Communication Experts and Foreign Media Outlets Visits Emerging Industry Enterprises in Zhongshan, Guangdong Province

BEIJING, Oct. 11, 2024 /PRNewswire/ -- On October 9, 2024, the delegation of international communication experts and foreign media outlets, themed "The World Comes to Zhongshan" and organized by the CICG Academy of Translation and Interpretation, visited several representative enterprises in Zhon...

2024-10-11 01:07 2351

Delegation of International Communication Experts and Foreign Media Outlets Visits Emerging Industry Enterprises in Zhongshan, Guangdong Province

BEIJING, Oct. 10, 2024 /PRNewswire/ -- On October 9, 2024, the delegation of international communication experts and foreign media outlets, themed "The World Comes to Zhongshan" and organized by the CICG Academy of Translation and Interpretation, visited several representative enterprises in Zhon...

2024-10-11 00:53 2005

111 Inc. Expands National Supply Chain Network with New Fulfillment Centers across South and Central China

SHANGHAI, Oct. 10, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that new fulfillme...

2024-10-10 18:02 3434

Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 9, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunolo...

2024-10-10 11:04 1304

Daewoong Pharmaceutical Unveils 'Innovative Drug Delivery Technologies' in Milan--From World's First Microneedle Therapy to Once-a-Month Obesity Treatment

MILAN, Oct. 10, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-jae Lee) announced on the 9th that they will present their cutting-edge drug delivery technologies, including the world's first microneedle-based drugs, at 'CPHI Worldwide 2024'—the world's largest phar...

2024-10-10 06:16 1608

Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics

SEATTLE, Oct. 9, 2024 /PRNewswire/ -- Arbele, a leading innovator in biopharmaceutical & biotechnology focused on targeting cadherin-17 (CDH17), is pleased to announce strategic collaborations in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of bisp...

2024-10-09 23:00 1276

Baird Medical Lists in the U.S. on the Nasdaq Exchange

Company Rings Opening Bell to Celebrate Closure of Business Combination and Begins Journey as a Public Company; Shares trade under "BDMD" Ticker FORT MILL, S.C., Oct. 9, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading micro...

2024-10-09 20:30 1427

New INTREPID Alliance Antiviral Landscape Report Highlights Urgent Need to Bolster R&D Pipeline in Support of Global Pandemic Preparedness Efforts

Current mpox outbreak underscores gaps in access to medical countermeasures to help mitigate the severity of future outbreaks CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Today, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral tr...

2024-10-09 19:00 1110

The CDE has Granted Breakthrough Therapy Designation to LBL-024, a Bispecific Antibody that Targets PD-L1 and 4-1BB, Developed by Leads Biolabs, for the Treatment of Extrapulmonary Neuroendocrine Carcinoma.

NANJING, China, Oct. 9, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, an anti-PD-L1/4-1BB bispecific antibody indepe...

2024-10-09 13:38 1535

Joint Venture Company Established for Incubation of Early Drug Discovery Programs; Investment from Takeda, Astellas and Sumitomo Mitsui Banking

TOKYO, Oct. 8, 2024 /PRNewswire/ -- Ciconia Bioventures Inc. (Representative Director, Founder CEO:Toshio Fujimoto, "Ciconia") today announced its establishment as a joint venture company based on a master agreement signed on April 22, 2024 by Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:...

2024-10-09 10:00 1285

Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials

KYOTO, Japan, Oct. 7, 2024 /PRNewswire/ -- Rege Nephro Co., Ltd. ( https://www.regenephro.co.jp/ ) is excited to  announcethat the company has successfully developed a funding plan of total approximately17 million dollar (2.5 billion JPY) in new Series B funding and ...

2024-10-09 07:39 2374

Seegene and Werfen Finalize Partnership Agreement on Technology-Sharing Initiative

* Werfen, a worldwide leader in specialized diagnostics, becomes the first European company to finalize the partnership agreement to join Seegene's technology-sharing initiative * The two companies will co-establish a NewCo in Spain to serve as a strategic hub inEurope, accelerating global ex...

2024-10-08 21:00 1627

LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance

GAITHERSBURG, Md., Oct. 8, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for in...

2024-10-08 20:30 3083

Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended To Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer

PFL-241/STX-241 is a highly selective, and potentially best-in-class fourth generation epidermal growth factor receptor ("EGFR") inhibitor One of two EGFR programs being developed with Scorpion Therapeutics CASTRES, France and BOSTON, Oct. 8, 2024 /PRNewswire/ -- Pierre Fabre Laboratories, a glo...

2024-10-08 20:00 1336

MicuRx Pharmaceuticals Announces Promising Results from MRX-5 Study for Treating Mycobacterium abscessus Infections

FOSTER CITY, Calif., Oct. 8, 2024 /PRNewswire/ -- MicuRx Pharmaceuticals is excited to announce the publication of groundbreaking research on MRX-5, a novel oral oxaborole prodrug, demonstrating significant potential in the treatment of pulmonary infections caused byMycobacterium abscessus (Mab),...

2024-10-08 13:38 991

Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC

ROCKVILLE, Md. and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that APG-2449, a FAK/ALK...

2024-10-08 10:26 1484

Sciwind Biosciences Announces Oral Presentation on Oral GLP-2 Research Progress at the 32nd United European Gastroenterology Week (UEG Week 2024)

BEIJING and HANGZHOU, China, Oct. 7, 2024 /PRNewswire/ -- The 32nd United European Gastroenterology Week (UEG Week 2024) will take place inVienna, Austria , fromOctober 12 to 15, 2024. UEG Week is the largest gastroenterology conference inEurope and one of the leading meetings worldwide. It brings...

2024-10-08 10:00 1254
1 ... 78910111213 ... 313

Week's Top Stories